Okyo Pharma Limited · NASDAQ:OKYO
Okyo Pharma — Eyecelerator Conference (April 2024)
14 slides from Okyo Pharma's conference presentation, Apr 4, 2024
Slide 1: OK-101 Phase 2 Trial to Treat Dry Eye Disease
OK-101 Phase 2 Trial to Treat Dry, Eye Disease OK YO PHARMA Nasdaq: OKYO EYECELERATOR CONFERENCE April 4, 2024
Slide 2: Disclaimer
Disclaimer By accepting and using this presentation, you will be deemed to agree not to disclose any information contained! herein except as may be required by law. Additionally, certain information contained in this presentation has been obtained from published sources prepared by other parties, wh
Slide 3: OK-101: A Lipid-Conjugated Chemerin Peptide
Chemerin Peptide OK-101: A Lipid-Conjugated Chemerin Peptide Linker Drug candidate with anti-inflammatory and ocular Chemerin Receptor pain reducing properties Modulates Anchored Lipid Lipid conjugated peptide chemistry minimizes drug __!nflammation OK-101 washout and enhances the potency Receptor l
Slide 4: Normalized Goblet Cells & Reduced Inflammatory CD4 T Cells
OK-101 Normalized Goblet Cells & Reduced Inflammatory CD4 T Cells* Enucleated Mouse Eyes from Scopolamine-Treated Dry-Eye Mouse Study Increased Mucin-Secreting Goblet Cells* Reduced Inflammato ers* OK-101 normalized goblet cell density OK-101 reduced count of CD4+ T cells Goblet cell density CD4: T
Slide 5: Reduced Neuropathic Corneal Pain (NCP) in Mouse Model
OK-101 Reduced Neuropathic Corneal Pain (“NCP”) in Mouse Model Ciliary Ligation Model* Illustrates OK-101 Potential to Reduce Ocular Pain Ciliary nerve ligation surgery to create the corneal neuropathic pain (CNP) model Long Ciliary Nerve Short Ciliary Nerve * Collaboration wth Or. Pedram Hamrah, Tu
Slide 6: Disrupts Dry Eye Cycle by Targeting Inflammation, Improving Tear Film Stability
OK-101 Disrupts Dry Eye Cycle by Targeting Inflammation, Improving Tear Film Stability and by Ameliorating Multiple Symptoms as Lacrimal gland aber flow 4 Mucous ayer agent layet aS 38,000,000 [- Lipid layer US DED patients OK-101 Reduces Inflammatory Markers 18,000,000 Diagnosed Meibomian aoatid wa
Slide 7: DED Phase 2 Trial Design
OK-101 DED Phase 2 Trial Design First Human Trial of O No K-101 Day-14 Day 1 Day15 Day29_-- Day57-— Day 85 | Placebo run | | i | in period | i i | Screening < ————e —: > Visit 1 Visit2. Visit 3 Visit 4 Visit S Visit 6 ft Randomization into one of three cohorts Study Overview Total Subjects: Enrolled
Slide 8: US Regulatory Requirements for Dry Eye Disease
US Regulatory Requirements for Dry Eye Disease Dry Eye: Developing Drugs for Treatment Guidance for Industry Sign and Symptoms (co-primaries, p<0.05, no unit difference required) - can be 9° achieved in separate studies if necessary Sign Only (e.g., Schirmer’s Responder ~) Rate >10 mm, clearing of c
Slide 9: Improvement in Conjunctival Sum Staining (Sign)
Improvement in Conjunctival Sum Staining (Sign) Data shown is change from baseline in Intent-to-Treat Population P values are vs placebo based on Wilcoxon rank sum test Lissamine Green Staining Fluorescein Staining Day 15, Day 29 Day 57 Day 85 Day 15 Day 29 Day 57 Day 85 LSM (SE) change from baselin
Slide 10: Significant Improvement in Tear Film Break Up Time (Sign)
Significant Improvement in Tear Film Break Up Time (Sign) Data shown is change from baseline in Intent-To-Treat Population P values are vs placebo based on Wilcoxon rank sum test LSM (SE) change from baseline (s) Day 15 Day29 Day 7 Day 85 20.05% OK-101 Placebo 10
Slide 11: Significant Improvement in Pain (Symptom)
Significant Improvement in Pain (Symptom) Data shown is change from baseline in Intent-To-Treat Population P values are vs placebo based on Wilcoxon rank sum test LSM (SE) change from baseline (VAS) “10 “12 14 “16 18 -20 Day 15 Day 29 Day $7 Day 85 20.05% OK-101 =e-Placebo "
Slide 12: Significant Improvement in Burning/Stinging & Blurred Vision (Symptoms)
Significant Improvement in Burning/Stinging & Blurred Vision (Symptoms) Data shown is change from baseline in Intent-To-Treat Population P values are vs placebo based on Wilcoxon rank sum test Day 15 Day 29 Day 57 Day 85 Day 15 Day 29 Day $7 Day 85 ° a 6 <4 | 3 | ge ‘1 | | e712 ; £ ssp rn ° 5 16 2 P
Slide 13: Significant Improvement in Symptoms by Patient Reported Daily Diary
Significant Improvement in Symptoms by Patient Reported Daily Diary Within First Two Weeks (P values are vs placebo based on Wilcoxon rank sum test) CARR LS mean (SE) change from baseline (score) -0.1 -025 Itching Eye Dryness P = 0.009 P = 0.00! 1.005% OK-101 y a Placebo Pain 3
Slide 14: Key Takeaways
Key Takeaways Significant drug effects were observed in multiple signs (conjunctival staining, TFBUT) and symptoms y (ocular pain, burning/stinging and blurred vision) of DED as early as the 15-days after dosing. Drug effect was durable throughout the trial for a number of endpoints. Significant imp